Your Patients Can't Find Their Insulin — Here's How to Help

As a provider managing patients with diabetes, you've likely heard from patients who can't find Insulin Aspart (NovoLog or Fiasp) at their pharmacy. The ongoing shortage has created real clinical risk — patients missing doses, rationing insulin, and experiencing preventable hyperglycemia and even diabetic ketoacidosis.

This guide provides a practical, step-by-step approach to help your patients maintain access to rapid-acting insulin during the current supply disruption.

Current Availability: What's Affected

As of early 2026, the shortage primarily affects Novo Nordisk products:

• Fiasp FlexTouch pens: Limited availability since mid-2024. No confirmed resolution date.
• Fiasp vials: Intermittent supply due to manufacturing delays.
• NovoLog vials and pens: More consistently available but experiencing regional spot shortages.
• Unbranded biologic Insulin Aspart: Discontinued by Novo Nordisk as of December 31, 2025.

The loss of the unbranded generic has been particularly impactful, as many cost-conscious patients depended on it. This has increased demand pressure on brand-name products and alternative rapid-acting insulins.

Why Patients Can't Find It

Understanding the root causes helps you counsel patients and manage expectations:

1. Manufacturing delays at Novo Nordisk — production challenges have affected multiple Insulin Aspart formulations for over a year
2. Generic discontinuation — the removal of the unbranded version reduced total market supply
3. Supply chain concentration — Novo Nordisk is the primary manufacturer of Insulin Aspart, creating a single point of failure
4. Rising demand — the diabetes population continues to grow, with over 38 million Americans now diagnosed
5. Regional variability — distribution patterns mean some areas are hit harder than others, making it unpredictable for patients

What Providers Can Do: 5 Practical Steps

Step 1: Direct Patients to Real-Time Availability Tools

Medfinder for Providers allows your office to check which pharmacies near a patient's location have Insulin Aspart in stock — in real time. This is far more efficient than having patients call pharmacy after pharmacy.

How to implement this:

• Add Medfinder to your office workflow — check availability before sending prescriptions
• Share the tool with patients: medfinder.com
• Consider sending prescriptions to pharmacies you've verified have stock

Step 2: Write Flexible Prescriptions

When supply is uncertain, flexibility in your prescriptions helps patients fill them:

• Specify "insulin aspart" generically when possible, allowing the pharmacy to dispense whichever formulation is available (NovoLog, Fiasp, or generic)
• Include "may substitute with insulin lispro" or contact your state pharmacy board to understand substitution rules for biologic insulins in your state
• Consider writing for both vials and pens — one formulation may be available when the other isn't
• Prescribe 90-day supplies when appropriate to reduce the frequency of refill challenges

Step 3: Have an Alternative Ready

When Insulin Aspart is truly unavailable, the following rapid-acting insulins are clinically appropriate alternatives:

• Insulin Lispro (Humalog / generic Insulin Lispro): The most direct substitute. Similar pharmacokinetic profile. Unit-for-unit conversion is generally appropriate. Generic version widely available and often more affordable.
• Insulin Glulisine (Apidra): Comparable rapid-acting profile. Less commonly stocked but available. Approved for pump use.
• Admelog (Insulin Lispro biosimilar): Biosimilar to Humalog. Often preferred by insurance formularies for cost reasons.
• Lyumjev (faster-acting Insulin Lispro): Consider for patients specifically transitioning from Fiasp, as both are ultra-rapid formulations.

For patient education on alternatives, share: Alternatives to Insulin Aspart.

Step 4: Connect Patients with Financial Assistance

Switching formulations or brands can change patient costs. Proactively connecting patients with savings programs prevents cost-related non-adherence:

• Novo Nordisk savings card: Eligible commercially insured patients pay as little as $35/month for NovoLog or Fiasp. Enroll at novolog.com/savings
• Novo Nordisk PAP: Free insulin for qualifying uninsured patients. No fee to apply. Start at novocare.com
• Medicare $35 cap: Remind Medicare Part D patients that insulin is capped at $35/month with no deductible under the Inflation Reduction Act
• Discount coupons: Generic Insulin Aspart available for as low as $74 through GoodRx. Insulin Lispro generics start around $30-$50 with coupons

For a comprehensive patient resource, share: How to Save Money on Insulin Aspart in 2026.

Step 5: Monitor Patients Closely During Transitions

When patients switch insulin formulations, even among rapid-acting analogs:

• Schedule a follow-up within 1-2 weeks of the switch
• Ask patients to increase blood glucose monitoring frequency during the transition
• Review patients using continuous glucose monitors (CGMs) for trend changes
• Pay special attention to patients transitioning from Fiasp to standard rapid-acting analogs, as the slightly different onset profile may affect postprandial control
• Document the reason for the switch in the chart for continuity and insurance purposes

Workflow Tips for Your Practice

Integrating shortage management into your clinical workflow can reduce burden on both staff and patients:

• Create a shortage protocol: Designate which alternative insulin to prescribe when Insulin Aspart is unavailable (e.g., Insulin Lispro as first-line alternative)
• Pre-authorize alternatives: If your patient's insurance requires PA for non-preferred insulins, submit the authorization proactively before the shortage forces an urgent switch
• Maintain a sample inventory: Keep NovoLog and Fiasp samples when available from pharmaceutical representatives to bridge patients during acute shortages
• Educate your front desk and nursing staff: Ensure they know to direct shortage-related calls to Medfinder and NovoCare (1-888-668-6444)
• Batch communication: When a new shortage affects a commonly prescribed medication, proactively notify affected patients via patient portal rather than waiting for individual calls

Alternatives at a Glance

For quick clinical reference:

• Insulin Lispro (Humalog): Onset 15 min, peak 1-2 hr, duration 3-5 hr. Pump compatible. Generic available ($30-$50 with coupon).
• Insulin Glulisine (Apidra): Onset 15 min, peak 1-2 hr, duration 3-5 hr. Pump compatible. Brand only ($200-$300).
• Admelog (Lispro biosimilar): Same profile as Humalog. Often formulary-preferred. $100-$150 with coupon.
• Lyumjev (ultra-rapid Lispro): Onset ~10 min, peak 1-2 hr. Consider for Fiasp transitions. Higher cost.
• Regular Human Insulin (Novolin R): Onset 30 min, peak 2-4 hr, duration 6-8 hr. OTC at Walmart ~$25/vial. Not a direct substitute — requires different meal timing. Emergency backup only.

Final Thoughts

The Insulin Aspart shortage is an ongoing challenge, but proactive provider involvement makes a measurable difference in patient outcomes. By leveraging availability tools like Medfinder, preparing alternative prescribing strategies, and connecting patients with financial resources, you can help ensure no patient goes without their mealtime insulin.

For the patient-facing version of this guide, share: How to Find Insulin Aspart in Stock Near You.

For a clinical overview of the shortage, see: Insulin Aspart Shortage: What Providers Need to Know.